Drug Class Detail

Drug Class HDAC Inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
CHR-3996 Tractinostat HDAC Inhibitor 34 Tractinostat (CHR-3996) is a selective Class I HDAC inhibitor, which may result in decreased tumor growth (PMID: 22553374).
Citarinostat ACY-241 HDAC Inhibitor 34 Citarinostat (ACY-241) selectively inhibits HDAC6, which potentially results in decreased tumor cell viability and reduced tumor growth, particularly in combination with other agents (PMID: 27926524, PMID: 28264055).
Romidepsin Istodax FK228|FR901228|NSC 630176|depsipeptide HDAC Inhibitor 34 Istodax (romidepsin) inhibits Class I HDACs, resulting in cell cycle arrest, apoptosis, and decreased tumor cell growth (PMID: 12208741, PMID: 12234611, PMID: 21258344). Istodax (romidepsin) is FDA approved for patients with cutaneous T-cell lymphoma (FDA.gov).
AR-42 HDAC42 HDAC Inhibitor 34 AR-42 is a histone deacetylase (HDAC) inhibitor, which may lead to increased apoptosis of tumor cells and decreased tumor growth (PMID: 23178755, PMID: 21778190).
Givinostat ITF2357 HDAC Inhibitor 34 Givinostat (ITF2357) is a pan-HDAC inhibitor, which promotes cell-cycle arrest and apoptosis of tumor cells (PMID: 24648290).
Vorinostat Zolinza SAHA|L-001079038|MSK390 HDAC Inhibitor 34 Zolinza (vorinostat) inhibits HDAC activity, resulting in cell-cycle arrest, decreased proliferation, and increased differentiation of tumor cells (PMID: 9501205, PMID: 11731433, PMID: 11016644). Zolinza (vorinostat) is FDA approved for use in cutaneous T-cell lymphoma (FDA.gov).
ACY-957 HDAC Inhibitor 34 ACY-957 is a small molecule inhibitor of HDAC1/2, which may result in increased H3K27ac, increased DNA damage, and impairment of DNA repair (PMID: 25605023).
Ricolinostat ACY-1215 HDAC Inhibitor 34 Ricolinostat (ACY-1215) is a selective inhibitor of HDAC6, which may decrease tumor cell viability and reduce tumor growth, alone or in combination with other agents (PMID: 22262760, PMID: 27926524).
CUDC-101 EGFR Inhibitor (Pan) 38 HDAC Inhibitor 34 HER2 Inhibitor 20 CUDC-101 is a small-molecule inhibitor of EGFR, ERBB2 (HER2), and class I and II HDACs, which has demonstrated activity in EGFR-inhibitor resistant tumor cell lines (PMID: 20388807, PMID: 23536719).
Dacinostat LAQ824 HDAC Inhibitor 34 Dacinostat (LAQ824) is an HDAC inhibitor, which promotes apoptosis of tumor cells via activation of the mitochondrial apoptotic pathway (PMID: 19383971).
Tacedinaline CI-994|N-acetyldinaline HDAC Inhibitor 34 Tacedinaline (CI-994) inhibits HDAC activity, which may result in decreased tumor growth (PMID: 18497959, PMID: 16391874).
SKLB-23bb HDAC Inhibitor 34 SKLB-23bb is a selective HDAC6 inhibitor, which may result in disruption of microtubule polymerization, inhibition of the cell-cycle, and induction of apoptosis (PMID: 29610282).
CUDC-907 Fimepinostat HDAC Inhibitor 34 PI3K Inhibitor (Pan) 34 CUDC-907 (fimepinostat) is a dual PI3K and HDAC inhibitor, which prevents activation of the PI3K-AKT-mTOR signal transduction pathway, inhibits tumor cell growth, and promotes apoptosis in cancer cells (PMID: 22693356).
4SC-202 HDAC Inhibitor 34 4SC-202 is a class I histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cells (PMID: 26773495).
KA2507 HDAC Inhibitor 34 KA2507 is a selective inhibitor of HDAC6, potentially leading to increased histone acetylation, thereby modifying gene expression and specifically, inhibiting Stat3 activity (NCI Drug Dictionary).
Tinostamustine EDO-S101 Chemotherapy - Alkylating 14 HDAC Inhibitor 34 Tinostamustine (EDO-S101) comprises the structure of the DNA alkylating drug bendumustine combined with the pan-HDAC inhibitor vorinostat, which may both induce DNA damage and inhibit DNA repair resulting in increased tumor cell death (PMID: 28753594).
Mocetinostat MGCD0103 HDAC Inhibitor 34 Mocetinostat (MGCD0103) selectively inhibits Class I histone-deacetelyases (HDACs), which may result in increased tumor cell death (PMID: 21317455, PMID: 20538840).
ST7612AA1 HDAC Inhibitor 34 ST7612AA1 is a second-generation pan-HDAC inhibitor, which leads to decreased proliferation and increased apoptosis of tumor cells (PMID: 25671299).
MPT0E028 HDAC Inhibitor 34 MPT0E028 inhibits histone deacetylases as well as Akt phosphorylation, resulting in increased tumor cell death and inhibition of tumor growth (PMID: 25669976).
Pracinostat SB939 HDAC Inhibitor 34 Pracinostat (SB939) is a histone deacetylase (HDAC) inhibitor, with limited activity against HDAC6, which may reduce tumor cell proliferation and tumor growth (PMID: 20197387).
M344 HDAC Inhibitor 34 M344 is an HDAC inhibitor, which may decrease proliferation and induce apoptosis of tumor cells (PMID: 17230517).
Abexinostat PCI-24781|S-78454|CRA-024781 HDAC Inhibitor 34 Abexinostat (PCI-24781) is an HDAC inhibitor, which induces tumor cell apoptosis and decreases tumor cell growth (PMID: 16731764, PMID: 25520806).
Quisinostat JNJ-26481585 HDAC Inhibitor 34 Quisinostat (JNJ-26481585) is a second-generation HDAC inhibitor, which increases histone acetlyation, and may increase tumor cell apoptosis and inhibit tumor growth (PMID: 24038993, PMID: 19861438).
Entinostat HDAC inhibitor SNDX-275|MS 275 HDAC Inhibitor 34 Entinostat (MS-275) inhibits HDAC activity, with selectivity towards HDAC1, 2, and 3, which results in increased histone acetylation, and potentially leads to decreased tumor cell proliferation and tumor growth (PMID: 19724929, PMID: 17383217).
CG200745 HDAC Inhibitor 34 CG200745 is an HDAC inhibitor, which increases tumor cell apoptosis and decreases tumor cell growth (PMID: 25781604, PMID: 28134290).
Trichostatin A TSA HDAC Inhibitor 34 Trichostatin A (TSA) inhibits histone deacetylase (HDAC) activity, which may lead to decreased tumor cell proliferation and viability and reduced tumor growth (PMID: 11309348, PMID: 22158273).
Valproic acid Depakene Depacon HDAC Inhibitor 34 Valproic acid inhibits HDAC activity, potentially resulting in decreased angiogenesis, increased tumor cell differentiation, and reduced tumor growth (PMID: 11742974, PMID: 14978230). Valproic acid is FDA-approved for use in treating seizures (FDA.gov).
Belinostat Beleodaq PDX101|NSC726630|PX-105684 HDAC Inhibitor 34 Beleodaq (belinostat) is an HDAC inhibitor, which promotes tumor cell apoptosis, potentially leading to decreased tumor growth (PMID: 12939461, PMID: 16928830, PMID: 17935615). Beleodaq (belinostat) is FDA approved for patients with relapsed or refractory peripheral T-cell lymphoma (FDA.gov).
Droxinostat NS 41080 HDAC Inhibitor 34 Droxinostat inhibits HDAC activity, with selectivity for HDAC3, 6, and 8, potentially resulting in decreased tumor cell growth (PMID: 20053768, PMID: 26947884).
Panobinostat Farydak LBH589 HDAC Inhibitor 34 Farydak (panobinostat) is an HDAC inhibitor, which induces cell-cycle arrest and decreases growth of tumor cells (PMID: 18349321, PMID: 19671764, PMID: 27802904). Farydak (panobinostat) is FDA approved, in combination with Velcade (Bortezomib) and dexamethasone, for multiple myeloma (FDA.gov).
Chidamide CS055|HBI-8000 HDAC Inhibitor 34 Chidamide (CS055) is an HDAC inhibitor, which may lead to increased apoptosis and decreased proliferation of tumor cells (PMID: 25384499).
TMU-35435 HDAC Inhibitor 34 TMU-35435 is an HDAC inhibitor, which induces cell-cycle arrest and apoptosis of tumor cells (PMID: 28233309).
OBP-801 YM753 HDAC Inhibitor 34 OBP-801 is a histone deacetylase inhibitor belonging to the cyclic peptide class, which may induce both cell cycle arrest and apoptosis (PMID: 18292931, PMID: 23900601).
Resminostat 4SC-201 HDAC Inhibitor 34 Resminostat (4SC-201) is a histone deacetylase inhibitor that induces chromatin remodeling, leading to growth inhibition and apoptosis in tumor cells (PMID: 20201941).
Molecular Profile Protein Effect Treatment Approaches
RB1 Q217* loss of function - predicted HDAC Inhibitor
RB1 inact mut loss of function HDAC Inhibitor
RB1 R445* loss of function - predicted HDAC Inhibitor
RB1 Y728* loss of function - predicted HDAC Inhibitor
RB1 S634* loss of function - predicted HDAC Inhibitor
RB1 C553* loss of function - predicted HDAC Inhibitor
RB1 R255* loss of function - predicted HDAC Inhibitor
RB1 R358* loss of function - predicted HDAC Inhibitor
RB1 S463fs loss of function - predicted HDAC Inhibitor
RB1 Q62* loss of function - predicted HDAC Inhibitor
RB1 E554* loss of function - predicted HDAC Inhibitor
RB1 E137* loss of function - predicted HDAC Inhibitor
RB1 Q344* loss of function - predicted HDAC Inhibitor
RB1 R320* loss of function - predicted HDAC Inhibitor
RB1 R579* loss of function - predicted HDAC Inhibitor
RB1 A10fs loss of function - predicted HDAC Inhibitor
RB1 Q504* loss of function - predicted HDAC Inhibitor
RB1 K319Nfs*13 loss of function - predicted HDAC Inhibitor
RB1 Q266* loss of function - predicted HDAC Inhibitor
RB1 Q344fs loss of function - predicted HDAC Inhibitor
RB1 L607I loss of function - predicted HDAC Inhibitor
RB1 G435* loss of function - predicted HDAC Inhibitor
RB1 E280* loss of function - predicted HDAC Inhibitor
RB1 S816* loss of function - predicted HDAC Inhibitor
RB1 E748* loss of function - predicted HDAC Inhibitor
RB1 W195* loss of function - predicted HDAC Inhibitor
RB1 W681* loss of function - predicted HDAC Inhibitor
RB1 E545* loss of function - predicted HDAC Inhibitor
RB1 R552fs loss of function - predicted HDAC Inhibitor
RB1 E48* loss of function - predicted HDAC Inhibitor
RB1 R621C loss of function - predicted HDAC Inhibitor
RB1 R556* loss of function - predicted HDAC Inhibitor
RB1 R272* loss of function - predicted HDAC Inhibitor
RB1 K765* loss of function - predicted HDAC Inhibitor
RB1 Q354* loss of function - predicted HDAC Inhibitor
RB1 E413* loss of function - predicted HDAC Inhibitor
RB1 A11fs loss of function - predicted HDAC Inhibitor
RB1 L797fs loss of function - predicted HDAC Inhibitor
RB1 R467* loss of function - predicted HDAC Inhibitor
RB1 K740* loss of function - predicted HDAC Inhibitor
RB1 loss loss of function HDAC Inhibitor
RB1 R251* loss of function - predicted HDAC Inhibitor
RB1 W99* loss of function - predicted HDAC Inhibitor
RB1 Q639* loss of function - predicted HDAC Inhibitor
RB1 R787* loss of function - predicted HDAC Inhibitor
RB1 Q575* loss of function - predicted HDAC Inhibitor
RB1 Q257* loss of function - predicted HDAC Inhibitor
RB1 R552* loss of function - predicted HDAC Inhibitor
RB1 R455* loss of function - predicted HDAC Inhibitor
RB1 C706F loss of function - predicted HDAC Inhibitor
RB1 L523fs loss of function - predicted HDAC Inhibitor
RB1 L199* loss of function - predicted HDAC Inhibitor
RB1 R698W loss of function HDAC Inhibitor